PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩170 per share · Prices as of the 2026-10-02 close
Core semiconductor operating profit has stayed in loss territory in recent quarters, while non-operating gains and progress in the D-SaLife healthcare venture are supporting both net income and market attention.
2025 revenue fell to KRW 127.6bn from KRW 138.3bn a year earlier, with operating margin narrowing to 1.9%.
The company posted operating losses for three consecutive quarters from 2025Q4 through 2026Q2, with the loss size widening.
Over the same period, net income attributable to owners rose unusually, driven by non-operating factors.
D-SaLife filed a confirmatory clinical trial protocol with Korea's MFDS in July 2026, and pilot clinical results from the UCLA collaboration were presented at a conference in early September.
The company is pushing to fully retire 695,491 treasury shares (3.33% of shares outstanding) within 2026 as part of a stronger shareholder return policy.
Founded in 2006, Dongwoon Anatech is a fabless system semiconductor company whose core products are AF (autofocus) Driver ICs and OIS (optical image stabilization) Driver ICs for smartphone cameras. The company has long held the top global sales position in AF Driver ICs.
In the OIS Driver IC market it splits share roughly evenly with Japan's Asahi Kasei, and its share within Samsung Electronics is said to have improved versus prior levels. Its OIS driver IC share among Chinese smartphone makers such as Huawei is estimated at around 80%.
The second business pillar is automotive electronics, where the company has developed Haptic Driver ICs, BLDC drivers, and LiDAR VCSEL Driver ICs in response to the digitalization of in-cabin buttons and touchscreens.
Domestically it has supplied haptic driver ICs for Hyundai Motor Group's premium Genesis GV80, G80 and GV60 models, and overseas it supplies components through French tier-1 supplier Valeo into electrified Mercedes-Benz, BMW and Jaguar vehicles.
The third pillar is a new digital healthcare venture, a saliva-based non-invasive glucose meter called D-SaLife, aimed at entering the blood glucose monitoring (BGM) and continuous glucose monitoring (CGM) markets.
As a fabless company, production is outsourced to external foundries and packaging/test houses, with dual- or triple-sourcing used across product lines to manage supply risk.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩30.1B | ₩3.1B | 10.3% |
| 2025Q3 | ₩30.7B | ₩70,533,145 | 0.2% |
| 2025Q4 | ₩36.7B | -₩59,343,169 | −0.2% |
| 2026Q1 | ₩30.8B | -₩1.9B | −6.0% |
| 2026Q2 | ₩26.1B | -₩5.1B | −19.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩50.1B | -₩6.3B | -₩8.4B | −12.5% | −39.8% | 198.0% |
| 2023 | ₩111.5B | ₩25.1B | ₩26.2B | 22.5% | 43.2% | 42.3% |
| 2024 | ₩138.3B | ₩17.5B | ₩24.7B | 12.6% | 34.7% | 38.6% |
| 2025 | ₩127.6B | ₩2.4B | ₩1B | 1.9% | 1.5% | 58.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue rose from KRW 50.1bn in 2022 to KRW 111.5bn in 2023 and KRW 138.3bn in 2024, but declined to KRW 127.6bn in 2025.
Operating profit swung from a loss of KRW 6.3bn (margin -12.5%) in 2022 to KRW 25.1bn (22.5%) in 2023 and KRW 17.5bn (12.6%) in 2024, before sharply narrowing to KRW 2.4bn (1.9%) in 2025.
Net income attributable to owners followed a similar pattern, falling from KRW 26.2bn in 2023 and KRW 24.7bn in 2024 to just KRW 1.0bn in 2025.
The quarterly trend shows clear deterioration: revenue of KRW 30.1bn and operating profit of KRW 3.1bn in 2025Q2 gave way to a near-breakeven KRW 30.7bn revenue and KRW 0.07bn operating profit in Q3, then an operating loss of KRW 0.06bn on KRW 36.7bn revenue in Q4.
Losses continued into 2026, with an operating loss of KRW 1.85bn on KRW 30.8bn revenue in Q1, widening to an operating loss of KRW 5.07bn on lower revenue of KRW 26.1bn in Q2.
In contrast, net income attributable to owners moved from KRW 1.47bn in Q3 to KRW 3.15bn in Q4, KRW 1.02bn in 2026Q1, and then jumped to KRW 19.3bn in Q2 -- a sharp divergence from the operating trend.
This gap reflects non-operating items such as asset or equity-related disposal gains rather than core semiconductor operations.
Across the trailing four quarters (2025Q3-2026Q2), operating results were mostly weak while net income rose on one-off factors, underscoring the need to distinguish core operating performance from bottom-line net income.
The end markets split broadly into smartphone camera components and automotive electronics.
On the smartphone side, patriotic-consumption ('guochao') trends in China have expanded the share of Chinese brands such as Huawei, Vivo and Honor, a dynamic analysts say could favor Dongwoon Anatech given its high share of Huawei's OIS driver IC business.
Samsung Securities noted in a March 2026 report that the company had improved its share within Samsung Electronics on the back of price competitiveness.
That said, the smartphone camera component market is driven by handset shipment volumes and camera-spec competition, leaving customer- and region-concentration as a structural risk.
In automotive electronics, the ongoing shift from physical buttons to display and touch interfaces underpins haptic feedback demand, but this market has long been dominated by U.S.-based Texas Instruments, leaving Dongwoon Anatech's share still limited.
The digital healthcare (non-invasive glucose monitoring) segment remains pre-commercial; industry estimates cited put the combined global BGM and CGM market at roughly KRW 40 trillion, though the timing and scale of any actual revenue contribution depend on regulatory progress.
Competitively, Dongwoon Anatech is a later entrant or relatively small player across most of its application areas, and narrowing the technology and capital gap with larger integrated semiconductor players remains a challenge.
The board approved a 'corporate value-up plan' on March 26, 2026, formalizing a stronger shareholder return policy.
The company is pursuing full retirement of its 695,491 treasury shares (3.33% of shares outstanding) within 2026, alongside plans to regularize shareholder communication through quarterly public Q&A disclosures.
The D-SaLife healthcare venture took a further step in its approval process by filing a confirmatory clinical trial protocol with Korea's MFDS in July 2026.
In the United States, pilot clinical results from the UCLA collaboration were presented at the Asian Society for Gland Research Symposium (ASGRS) in early September; a company representative said D-SaLife's saliva glucose readings matched certified glucose-monitoring devices 99% of the time, versus 85% for existing meters.
However, this is a small-scale pilot study, and the formal MFDS confirmatory trial, product approval, and post-Pre-Submission FDA procedures are still in progress.
On the semiconductor side, customer diversification in the smartphone OIS/AF lineup and expansion into automotive haptic and BLDC products are ongoing, but given the recent quarterly operating trend, no formal company guidance pointing to a near-term margin recovery has been confirmed.
The company's medium-term direction combines restoring profitability in its core semiconductor business with building a new growth driver through D-SaLife's approval and licensing process.
Compared with 2023-2024, when operating profit was generated on a normal basis, the current share price trades at a considerably higher multiple relative to the much smaller recent earnings base.
On a price-to-book basis, the shares also carry a sizable premium to net assets, which can be read as reflecting both hopes for a recovery in core semiconductor profitability and the option value attached to the D-SaLife venture.
Even though the company has recently expanded its dividend payout, the dividend yield implied at current price levels is estimated to run below the sector average.
Because operating results were mostly in loss over the trailing four quarters while net income rose on non-operating factors, conventional earnings-based valuation metrics warrant particular caution in this period.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
In March 2026 the board approved a corporate value-up plan including full retirement of 695,491 treasury shares (3.33%) and quarterly shareholder communication. The company has also steadily expanded its dividend payout in recent years.
The combination of a reduced float and a larger payout can be read as a signal of intent to enhance shareholder value.
D-SaLife filed a confirmatory clinical trial protocol with Korea's MFDS in July 2026, and pilot clinical results from the UCLA collaboration were presented at an international symposium in early September.
A company representative said the pilot study showed higher reproducibility for saliva glucose readings than existing meters (99% versus 85%).
Further procedures remain before approval, but the venture is drawing attention as an attempt to commercialize what would be the world's first non-invasive saliva-based glucose meter.
The company's OIS driver IC share among Chinese smartphone makers such as Huawei is estimated at around 80%, and its share within Samsung Electronics is also said to have recently improved.
In automotive electronics, applications have expanded through Hyundai Motor Group's Genesis lineup and supply into Mercedes-Benz, BMW and Jaguar via Valeo. A broadening customer base across both the smartphone and automotive pillars could help reduce reliance on any single customer.
The company posted operating losses for three straight quarters from 2025Q4 through 2026Q2, with the loss widening from KRW 0.06bn to KRW 5.07bn. Revenue over the same period fell from KRW 36.7bn to KRW 26.1bn. No clear signal supporting a near-term recovery in core semiconductor profitability has yet been confirmed.
Over the trailing four quarters, net income rose even as operating profit deteriorated, a pattern attributed largely to non-operating items such as asset or equity disposal gains. The sustainability of such earnings depends on discrete events rather than recurring operations.
If similar non-operating gains fail to recur, there is a possibility that the net income trend could weaken again.
D-SaLife remains pre-commercial, and a company representative has previously described one adjustment to the commercialization timeline. Both the domestic MFDS confirmatory trial and product approval process and the formal U.S.
FDA procedures are still ongoing, leaving the actual timing of revenue recognition uncertain. If this resource-intensive new venture is further delayed, the R&D cost burden could persist.
The OIS market is split with Japan's Asahi Kasei, and the haptic market has long been dominated by U.S.-based Texas Instruments. Revenue is relatively concentrated among specific customers such as Huawei and Samsung Electronics, and results are heavily influenced by handset shipment volumes and camera-spec competition. A technology and capital gap with larger integrated semiconductor players remains.
D-SaLife requires both a domestic MFDS confirmatory trial and product approval, as well as formal U.S. FDA procedures, before commercialization. The approval timeline has been adjusted once before, so further delays cannot be ruled out. Market expectations for the venture could shift materially depending on the regulatory outcome.
The recent gap between quarterly operating profit and net income has been large, with top-line and bottom-line income statement metrics moving in opposite directions. Greater reliance on non-operating gains can reduce the predictability of results. If operating profit fails to improve, net income could contract again going forward.
The 2026Q3 regular report and earnings release should be checked to see whether the operating loss trend continues and whether revenue recovers.
Further progress on D-SaLife's MFDS confirmatory clinical trial protocol (approval and trial start) should be monitored.
Completion of the retirement of 695,491 treasury shares (3.33%) per the March 2026 board resolution should be checked.
When full-year 2026 results are finalized, both the continuation of the dividend policy and the degree of recovery in core semiconductor operating margin should be checked.
Dongwoon Anatech's core semiconductor business, which posted double-digit operating margins in 2023-2024, has faced clear margin pressure since 2025, recording operating losses for three consecutive quarters from 2025Q4 through 2026Q2.
Over the same period, net income attributable to owners rose unusually on non-operating factors, underscoring the need to interpret core operating performance separately from bottom-line net income.
The company has strengthened shareholder returns through its March 2026 corporate value-up plan, including full retirement of treasury shares and an expanded dividend, while the D-SaLife healthcare venture has progressed through its approval process in stages, including a July 2026 domestic confirmatory trial protocol filing and early-September presentation of pilot clinical results from the UCLA collaboration.
Formal domestic and U.S. regulatory approvals remain in progress, however, and the actual commercialization timing and revenue contribution have not been determined.
Customer diversification in the smartphone OIS/AF business and expansion into automotive electronics applications continue, but the gap with larger competitors such as Texas Instruments and reliance on specific customers remain structural challenges.
Ultimately, the pace of profitability recovery in the core semiconductor business and the progress of D-SaLife's approval and licensing process are likely to be the key variables shaping future results and business direction.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.